Clinical Implications of "Cardiovascular Disease in Chronic Kidney Disease" : A Focus on Early Detection and Intervention DCDC Kidney Care

Dr Prem Agarwal[1]*, Dr Deepak Agarwal[2]*, Dr Yasir Anis[3]*
DCDC Health Services Pvt. Ltd.

[1]*MBBS, MD Internal Medicine,
DNB Internal Medicine, DNB (Cardiology),
Senior Physician Cardiologist,
premanita@hotmail.com

[2]*MD-Physician (St. Petersburg State Medical University),
MBA (Academy of Hospital Administration- Subharti University),
Vice President - DCDC Kidney Care,
drdeepak@dcdc.co.in

[3]*MD-Physician (Rostov State Medical University),
Sr. Manager - DCDC Kidney Care,
clinical_manager@dcdc.co.in

Abstract

This paper aims at investigating the interconnection of Chronic Kidney Disease (CKD) and Cardiovascular Disease (CVD) to address the problem of delay in the detection and implementation of early control measures. Chronic kidney disease that manifests itself through the progressive reduction of kidney function has become widespread and serves as a cardiovascular risk marker for a considerable part of the population as has been pointed out, CKD is usually identified in patients with hypertension and diabetes. CVD is the main cause of death in patients with CKD, and the cardiovascular events here are much higher than in the general population. The exact relationship between CKD and CVD includes the uremic toxins factors that cause endothelial dysfunction and inflammation as well as vascular calcification. The study brings into focus various screening approaches and discusses biomarkers such as cardiac troponins and NT-proBNP and other imaging methodologies like echocardiographic and coronary artery calcium scoring. The aforementioned drug classes that including ACE inhibitors, ARBs, statins, and SGLT2 inhibitors are mentioned to be used in top with pharmacological approaches while recommending certain dietary changes and other lifestyle changes. However, there are still deficiencies in the managing of CVD in CKD patients and the further research must be done, particularly in the field of early screening, diagnosis and individualized cure for patients. The findings in italics underscore the need for incorporating newer clinical protocols and policies in an effort to enhance the quality of patient care and in the process marginally alter the health care scope.

1. Introduction

1.1 Chronic Kidney Disease (CKD)

CKD is characterized by a gradual and permanent reduce in kidney function, identified by a "Glomerular Filtration Rate (GFR)" of less than 60 ml/min/1.73 m² for at least three months, regardless of the underlying cause. Indicators of kidney impairment may include albuminuria, abnormal urine sediment, or structural abnormalities detectable through imaging. CKD is a global health issue, affecting approximately 10-15% of the adult population, with higher prevalence among individuals over the age of 60. The condition is prevalent among those with hypertension and diabetes, which are leading contributors to CKD. The impact of CKD varies across different regions of the world. It is higher in LMICs where early detection and management are sought. Furthermore, CKD prevalence is worse in Black, Hispanic, or Indigenous individuals than in white people because of higher predisposing factors, including hypertension and diabetes, poor living standards, and inadequate access to healthcare services. CKD is also classified according to GFR, into five stages that indicate the degree of kidney dysfunction [Table 1].

Stage 1: The CKD's first stage is characterized by kidney damage with normal or high GFR (≥ 90 mL/min/1. 73 m²). This stage is often asymptomatic and CKD may not be identified.

Stage 2: A GFR of 6089 mL/min/1. 73 m² with kidney damage. It is asymptomatic, but there may be signs of renal dysfunction.

Stage 3: Kidney damage with a moderate decrease in kidney function eGFR 3059 mL/min/1. This stage is further divided into stage 3a with a GFR of 4559 and stage 3b with a GFR of 3044. Some of the early symptoms that patients may develop include fatigue, edema, and alteration in urinary output.

Stage 4: Moderately reduced GFR (1529 mL/min/1.73 m²). The symptoms become severe and the patient may suffer from anemia, bone diseases, and cardiovascular diseases.

Stage 5: Kidney failure or end-stage renal disease (ESRD) (eGFR <15 mL/min/1. 73 m² or on dialysis). At this stage, the kidneys are severely affected and the patient needs renal replacement therapy, which can be dialysis or kidney transplantation to live[3].

The staging of CKD is crucial in defining the treatment plan and patient outcomes. Stages 13 and 45 are mainly palliative, focusing on preventing disease progression and complications, while stages 45 are more challenging and include preparation for renal replacement therapy.

Table 1: the stages of CKD

Stage	GFR (mL/min /1.73 m²)	Kidney Damage	Symptoms	Examples	Management Focus
1	≥ 90	Kidney damage	Asymptomatic	Normal GFR, possible albuminuria	Prevention, monitoring
2	60-89	Kidney damage	Asymptomatic, possible signs of renal dysfunction	Mild decrease in GFR	Monitoring, early intervention
3a	45-59	Moderate decrease	Fatigue, edema, alteration in urinary output	Moderate decrease in GFR	Managing symptoms, slowing progression
3b	30-44	Moderate decrease	Fatigue, edema, alteration in urinary output	Significant decrease in GFR	Managing symptoms, slowing progression
4	15-29	Severely reduced	Anemia, bone diseases, cardiovascular diseases	Severe decrease in GFR	Preparation for renal replacement therapy
5	< 15 or on dialysis	End-stage renal disease (ESRD)	Severe symptoms, requiring renal replacement therapy	End-stage renal failure	Renal replacement therapy (dialysis or transplantation)

1.2 Cardiovascular Disease (CVD)

CVD refers to several disorders that affect the heart and blood vessels. It is said to be the major cause of ailments and fatalities globally and accounts for 17% of all deaths. CVD is responsible for 9 million deaths annually and claims 31% of all deaths in the developing world. CVD encompasses a range of diseases including CAD which is common and can cause death, heart failure in which the heart cannot pump blood correctly, arrhythmias which can cause stroke or heart failure and cerebrovascular diseases including stroke. This happens when the brain's blood supply is interrupted. Coronary artery disease (CAD) involves the buildup of plaque in the coronary arteries, leading to narrowed arteries and reduced blood flow to the heart, potentially causing angina or heart attacks (myocardial infarction). Heart failure may be caused by diseases like CAD, hypertension, and valvular heart disease; the patients may experience shortness of breath, fatigue, and edema. Atrial fibrillation is a common type of heart rhythm problem that raises the danger of stroke and is more frequent in patients with CVD. Stroke is among the severe forms of CVD that leads to long-term disability and increased expenditure on health care [5]. CVD is a disease that occurs in both the young and the old, both males and females, and all the regions of the world though their occurrence rate is not the same for all the groups. CVD is the primary reason for mortality in developed nations. It is rapidly becoming a leading concern in developing regions due to factors like smoking, unhealthy diets with lack of physical activity, and alcohol consumption. In the United States, CVD impacts 47.8% of the population; CAD and stroke, are among the most widespread diseases [6] [Table 2]. CVD cases are more common in the elderly, starting from the age of 60 years and above, with a prevalence of about 45%. Men are more vulnerable to CVD at a relatively younger age, but after menopause, women have rates that are quite close to those of older men. Since CVD and its risk factors are prevalent, effective measures of prevention and early diagnosis of CVD are critical [7].

Table 2: Summary of Cardiovascular Disease (CVD)

Type of CVD	Causes	Symptoms	Global Prevalence	Risk Factors	Public Health Implications
CAD	Atherosclerosis, plaque buildup in coronary arteries	Angina, myocardial infarction, chest pain	Leading cause of death globally	Hypertension, smoking, high cholesterol, diabetes	The major cause of ischemic heart disease is significant healthcare costs
Heart Failure	CAD, hypertension, valvular heart disease	Shortness of breath, fatigue, fluid retention	High in elderly populations	Hypertension, CAD, diabetes, obesity	Leading cause of hospitalization among older adults
Arrhythmias (e.g., Atrial Fibrillation)	Abnormal electrical activity in the heart	Irregular heartbeats, dizziness, palpitations	Common in both general and patient populations	Hypertension, CAD, age, heart failure	Increased risk of stroke complicates heart failure management
Stroke (Cerebrovascular Disease)	Ischemic (blood clots), hemorrhagic (bleeds)	Sudden weakness, speech difficulty, paralysis	The major cause of long-term disability	Hypertension, smoking, atrial fibrillation, diabetes	High morbidity and mortality, significant rehabilitation costs
Peripheral Artery Disease (PAD)	Atherosclerosis in peripheral arteries	Leg pain, cramping, ulcers	High in smokers, diabetics	Smoking, diabetes, high cholesterol	Increased risk of heart attack, stroke, amputation
Hypertensive Heart Disease	Longterm high blood pressure	Headache, dizziness, chest pain	Widespread globally	High blood pressure, obesity, sedentary lifestyle	A major contributor to heart failure, stroke, kidney disease

1.3. Link Between CKD and CVD

It is well-established that there is a strong connection between CKD and CVD. Multiple case-control and longitudinal studies indicate that patients with CKD face a significantly elevated risk of developing CVD. The rate of cardiovascular-related mortality among CKD patients is substantially higher, estimated to be up to twenty times greater than that of the general population, making CVD the leading cause of death in these patients. This heightened risk is observed at all stages of CKD but becomes particularly pronounced in the advanced stages, where nearly half of the deaths are due to cardiovascular complications. Clinical studies such as the "Chronic Renal Insufficiency Cohort (CRIC)" have demonstrated that declining kidney function is associated with a greater likelihood of conditions such as myocardial infarction, stroke, and heart failure. Similarly, the Framingham Heart Study, a landmark research effort in cardiovascular risk assessment, has confirmed that individuals with impaired kidney function face an increased risk of cardiovascular events.

The relationship between CKD and CVD is complex and bidirectional, influenced by numerous factors. Patients with long-term CKD often exhibit traditional cardiovascular risk factors such as high blood pressure, diabetes, abnormal lipid levels, and smoking. However, CKD also introduces additional risk elements that are specific to kidney dysfunction rather than being solely linked to diabetes. For instance, impaired kidney function leads to the accumulation of uremic toxins, which contribute to endothelial damage, oxidative stress, and inflammation—key processes that drive atherosclerosis and vascular calcification [10]. Another CKD-related issue, hyperphosphatemia, promotes vascular calcification and is a strong predictor of cardiovascular events and mortality. Additionally, complications like anemia and fluid overload further exacerbate cardiovascular problems, leading to conditions such as left ventricular hypertrophy (LVH) and heart failure. Notably, LVH has a strong association with increased risks of cardiovascular events and death. These pathophysiological mechanisms explain the bidirectional epidemiologic association between CKD and CVD, in which kidney disease significantly affects cardiovascular diseases [11].

1.4 Significance of Early Detection and Intervention

Thus, in patients with CKD and CVD, the risk of further cardiovascular events remains elevated, so it is necessary to carry out early diagnosis of the disease and adequate therapy. Some of them include; those with high blood pressure, diabetes, or those who have a relative with kidney, heart diseases. The diagnostic activities include estimating the serum albuminuria, GFR, cardiac troponins, with the application of echocardiography and the coronary artery calcium score. Changes in life style and medical treatment of CV risk factors including hypertension, abnormally elevated blood glucose and dyslipidaemia should be initiated in CKD patients.

[Table 3]. For this reason, overall cardiovascular risks, as well as hyperphosphatemia and anemia associated with CKD can be controlled. LINet, isomers, statins, and SGLT2 inhibitors are favorable for CKD patients regarding cardiovascular effects. The other aspect of management that is of the essence in these patients encompasses diet modifications, cessation of smoking, and other types of exercises [6]. Actually, the prevention of CV risk factors in the early stage and aggressive intervention are not only useful for reducing the incidence and mortality of CV events and for ameliorating the progression of renal disease in patients with CKD. Of course, such a dual advantage suggests that the management of CKD and its cardiovascular complications requires an aggressive approach.

Table 3: The significance of early detection and intervention for CKD and CVD

Aspect	Details	HighRisk Populations	Screening Methods	Interventions	Benefits
Significance	Early detection and intervention are crucial for mitigating risks and improving outcomes.	Hypertension Diabetes Family history of kidney/heart disease	Biomarkers: albuminuria, GFR, cardiac troponins Imaging: echocardiography, coronary artery calcium scoring	Traditional risk factors: blood pressure, blood glucose, lipid levels CKD-specific treatments: hyperphosphatemia, anemia	Reduces cardiovascular morbidity and mortality Slows progression of kidney disease
Pharmacological Interventions	ACE inhibitors ARBs Statins SGLT2 inhibitors	CKD patients CVD patients	Regular monitoring of biomarkers and imaging results	Reduces cardiovascular events Improves kidney function	Enhances patient outcomes Lowers healthcare costs
Non Pharmacological Approaches	Dietary modifications Smoking cessation Regular physical activity	General population Patients with lifestyle-related risk factors	Regular assessments by healthcare professionals Lifestyle monitoring	Supports overall cardiovascular and kidney health Complements pharmacological treatment	Promotes long-term health Reduces reliance on medication

2. Pathophysiology and Clinical Manifestations of CVD in CKD

In CKD, CVD is related to the interaction between fluid retention, hypertension, and dyslipidemia. Reduced capacity of the kidneys to control blood pressure and volume of fluids also results in increased arterial wall stiffness and 'endothelial dysfunction' and is involved in the progression of atherosclerosis. From a clinical perspective, patients may have heart failure, ischemic heart disease, and elevated cardiovascular mortality. Management of the patient includes evaluation of renal function and cardiovascular risk factors.

2.1 Specific Risk Factors for CKD

There is a substantial, modifiable association of hypertension with both CKD and future CVD. Persistent hypertension in CKD patients increases the risk of kidney disease and is the cause of cardiovascular diseases. It increases workload on the heart hence precipitating conditions such as left ventricular hypertrophy, heart failure and stroke. Likewise, diabetes mellitus is another clearly recognised risk factor for both, CKD and CVD. Hyperglycaemia results in endothelial dysfunction, atherogenesis and microvascular disease, all of which have adverse cardiovascular impact on CKD. Diabetic nephropathy is potential cause of CKD and plays a significant role in cardiovascular diseases. Also, 'lipid abnormalities' are common in patients with CKD, dyslipidemia being defined by increased triglycerides and decreased HDL cholesterol levels. This type of dyslipidemia is central to atherosclerosis and cardiovascular diseases, and, as a rule, exhibits poor outcomes with traditional lipid-modulating treatments [16] [Fig 1].

2.2 Specific Risk Factors for CVD

When there is a reduced kidney clearance the uremic toxins are generated and acts on the body system and results in cardiovascular diseases. These toxins impair endothelial function, stimulate inflammation, and are associated with LVH and vascular calcification that is characteristic for CKD patients [17]. These markers are linked with inflammation and oxidative stress that are characteristic of patients with CKD; they are further involved with cardiovascular complications. Higher levels of CRP, pro-inflammatory cytokines and tissue and cellular oxidative stress-related damage are found in CKD patients with atherosclerosis, myocardial damage and heart failure. Furthermore, hyperphosphatemia which is present in the majority of CKD patient contribute to the development of vascular calcification and cardiovascular disease. The filing of calcium- phosphate complexes in artery lead to the strengthening and the hardening of the arterial walls further complicating hypertension and the burden on the heart [8] [Fig 1]



Fig 1: Radar diagram showing risk factors for CKD and CVD

Figure 1 illustrates the various risk factors associated with CKD and CVD. The radar diagram highlights the overlapping and distinct risks, such as hypertension, diabetes, and hyperlipidemia, which contribute to the progression of CKD and its impact on cardiovascular health. It emphasizes the importance of monitoring these interconnected risk factors to manage both CKD and CVD effectively

2.3 Impact of Chronic Kidney Disease on Cardiovascular Status

Advancement of CVD about CKD Stages: The cardiovascular risk increases gradually throughout the evolution of CKD: from the early to the late stage. The cardiovascular risk in stages of CKD is raised due to traditional and CKD-related risk factors. In stage 3 and 4 of CKD, uremic toxins, worsening of dyslipidemia and inflammation progress cardiovascular disease[20]. Hemodynamic Changes: Chronic renal disease is defined by alterations in the blood flow and filtration rate and is associated with fluid retention and a rise in vascular resistance and pressure. Several of these modify the process of LVH, heart failure, and arrhythmias in CKD patients more, thereby serving to progress the cardiovascular risk in those patients [21] [Table 4].

Table 4: Impact of Chronic Kidney Disease on Cardiovascular Status

Aspect	CKD Early Stage	CKD Late Stage	Uremic Toxins	Inflammation
Advancement of CVD about CKD Stages	Increased cardiovascular risk	Further increased cardiovascular risk	Low impact	Moderate
Traditional Risk Factors	Present	Persisting	Not significant	Elevated
CKD-Associated Risk Factors	Emerging	Severe	Significant increase	Severe
Hemodynamic Changes	Minimal hemodynamic changes	Fluid overload increases vascular resistance	Contributes to vascular damage	Contributes to vascular and cardiac damage
Specific Cardiovascular Outcomes	Subclinical LVH, early atherosclerosis	Advanced LVH, heart failure, arrhythmias	Promotes atherosclerosis, LVH	Exacerbates atherosclerosis, myocardial injury

2.4 Symptoms of "Cardiovascular Disease in Chronic Kidney Disease"

Left ventricular hypertrophy (LVH) is commonly found in patients with chronic kidney disease (CKD) attributed largely to hypertension, increased workload, fluid overload or toxic products. LVH increases the risk of heart failure; arrhythmia and sudden cardiac death by a variable known to be substantially higher by LVH [24]. Reduced pumping capacity of the heart is also common in CKD patients, particularly when fluid overload is present, there is left ventricular hypertrophy, and damage to the myocardial fibres. Heart failure management in these groups of patients remains complex, especially concerning issues related to fluid overload as well as treatment options that affect renal function. Secondly, patients with CKD are vulnerable to arrhythmias such as atrial fibrillation which are associated with maintenance of electrolyte imbalance, LVH and myocardial fibrosis. Some of these arrhythmias have the potential to cause stroke and are part of the general treatment plan of cardiovascular disease in CKD patients [25]. CAD is another fatal and prevalent affliction in the indicated population; it also plays a role in causing high mortality and morbidity rates. Cardiac risk factors intrinsic to CKD include uremic toxins and vascular calcification along with usual cardiovascular risk factors such as hypercholesterolaemia and hypertension which contribute to progression of CAD in CKD patients [25] [Figure 2].



Fig 2: Pie chart showing the contribution of factors to CAD in CKD factors

The pie chart breaks down the contributions of different factors to the development of CAD in patients with CKD. It categorizes factors like uremic toxins, vascular calcification, and hypertension, showcasing their relative impacts. This visual representation provides a clear understanding of the multifaceted nature of CAD in CKD patients, underscoring the importance of addressing each component for effective disease management

2.3 Diagnostic Challenges in CKD

This makes the diagnosis of CVD in CKD patients difficult, since renal function changes also the troponins and natriuretic peptides specificity [26]. Echocardiography and coronary artery calcium scoring are two imaging modalities; however, their application and measurement in CKD patients should not be overemphasised [27]. Renal disease alters the management of cardiovascular drugs and may modify the manifestation of CVD. For instance, newton tried to determine the quality of life of CKD patients after six months and they found difficulty in the diagnosis of cardiac symptoms such as heart failure because the symptoms may be dominated by the effects of edema [28]. Cardiovascular disease and chronic kidney disease are primary comorbid diseases because the signs and symptoms are closely related to tiredness, breathlessness, and fluid retention. This means that the two conditions must be tackled systematically to guarantee that the appropriate treatment measures are availed [29].

3. Early Detection

The early detection of cardiovascular disease in those with CKD is important since patients with CKD are more likely to die if they have CVD. In many cases, CKD patients can have no or very subtle cardiovascular disease symptoms, so routine measurements should be performed like blood pressure, lipid profile, and left ventricular mass. Early identification of such markers is crucial since early management may be applied that may help to decelerate both CKD and CVD, thereby improving the prognosis of the patients.

3.1 Screening Strategies for CVD in CKD

Screening and Assessment Instruments: Performed screening for CVD is crucial in CKD patients since the morbidity and mortality for the disease are high. Risk estimation is highly valuable and useful for management of CKD because it helps in risking of patients with CVD. There are two types of these tools: The first set of models employ the CV risk factors, namely age, hypertension and diabetes in conjunction with CKD risk factors – eGFR and albuminuria. For instance, as extended from the Framingham Risk Score and even the ASCVD risk calculator, the process of generalizing the rotated cubes to accommodate CKD specific input data for use by physicians for enhanced risk assessment is relatively easy [30]. Thus, early identification of such patients allows a healthcare provider to manage the patient such that the patient does not develop cardiovascular complications.

Role of Biomarkers: Biomarkers are utilized effectively in the identification of early cardiovascular disease in patients with chronic kidney disease. CTn and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are of particular worth. The cTn represents myocardial injury and is often increased in CKD patients regardless of the presence of an acute coronary syndrome. However, this increase can cause diagnostic dilemma because there may be an overlap with other non-cardiac aetiologies. But their variations with regard to time are quite informative in estimating the probability of the worst cardiovascular outcomes [31]. Another cardiac stress test, the NT-proBNP is also elevated in CKD patients with its usage in determining the prognosis of heart failure and mortality. Nonetheless, these biomarkers should be used cautiously about renal function to eliminate false-positive findings and subsequent management [32].

Imaging Techniques: Echocardiography and coronary artery calcium scores are very important diagnostic tools on early diagnosis of cardiovascular disease in patients with chronic kidney disease. Echocardiography is often used to evaluate LVH, systolic and diastolic dysfunction, and valves disorders which are prevalent in CKD population [34]. LVH identified with echocardiography is a useful predictor of cardiovascular events and mortality in this population of individuals. These data combined with CAC scoring, a method of kilovoltage attenuation that accurately measures the extent of coronary artery calcification without requiring invasive procedures, also provides further prognostic value. raised CAC is associated with a higher prevalence CAD, which is common in patients with CKD because of increased tendency to develop vascular calcification. Therefore, using all these imaging methods help to determine the cardiovascular risk in patient with CKD and hence come up policy that will enable effective and timely management [Table 5].

Table 5: Screening Strategies for "Cardiovascular Disease" in "Chronic Kidney Disease"

Screening Strategy	Description	Tools/Instruments	Relevance	Key Considerations
Risk Assessment Tools	Use of combined conventional and CKD-specific factors to evaluate CVD risk.	Framingham Risk Score, ASCVD risk calculator	Identifies high-risk CKD patients for targeted intervention.	Modify tools to include CKD-specific factors like eGFR.
Cardiac Biomarkers	Measurement of biomarkers associated with myocardial damage and cardiac stress.	Cardiac Troponins (cTn), NT-proBNP	Useful for assessing myocardial damage and heart failure risk.	Interpret cautiously due to overlap with renal conditions.
Echocardiography	Imaging technique for evaluating cardiac structure and function in CKD patients.	Echocardiogram	Assesses left ventricular hypertrophy (LVH) and heart dysfunction.	LVH is a predictor of cardiovascular events.
Coronary Artery Calcification (CAC) Scoring	Non-invasive measure of coronary artery calcification for assessing CAD risk.	CAC Scoring	Indicates risk of coronary artery disease (CAD) through calcification.	High CAC scores are common in CKD patients.
Heart Failure Risk Evaluation	Use of biomarkers and imaging to evaluate the risk of heart failure in CKD patients.	NT-proBNP, Echocardiography	Helps in the early detection and management of heart failure.	Requires careful interpretation of renal function.
Integrated Assessment	Combining various assessment methods for a comprehensive evaluation of cardiovascular risk in CKD patients.	Risk Tools, Biomarkers, Imaging Techniques	Provides a thorough risk assessment and guides intervention.	Utilize a multi-modal approach for accurate diagnosis.

3.2 Advantages of Early Detection

***Reducing Morbidity and Mortality**:* The mortality and complication rates of CKD patients with CVD can be reduced if the disease is diagnosed early. This means determining the right therapies in the early stages; these consist of antihypertensive, statins, and antiplatelet classes shown to reduce significant CV events. For example, employing RAS inhibitors in patients with CKD has demonstrated the ability to lower the incidence of heart failure and cardiovascular death by controlling blood pressure as well as quantities of proteins in urine. And, early integration also facilitates control of the patient's lifestyle by diet and smoking which have been known to contribute to cardiovascular diseases.

***Managing CKD to Avoid Development of ESRD**:* Another advantage of early recognition of CVD in CKD patients is unavoidably preventing the progress from CKD to ESRD. The relationship between CVD and CKD exists; heart failure and ischemic heart disease are leading diseases, which worsen

CKD sharply [37]. To ensure proper management of this disease and possibly avoid having to go for dialysis or a kidney transplant one has to monitor their blood pressure and hyperlipidemia [38]. This simply implies that should the cardiovascular risk factors that underline progression to ESRD be effectively managed then the progression can be slowed hence improving this patient life's quality.

Improving Quality of Life: To be able to diagnose CVD in patients with CKD and not only add years to their lives but also the quality of life. Heart diseases including heart failure and arrhythmias are leading causes of immobility and poor quality of life in CKD patients [39]. If identified and treated at the early stages, the patient can recommend improved levels of self-reliance and perhaps reduce the number of admissions. Moreover, patient information and feedback, together with constant supervision, promote patient participation in their treatment process. This active participation brings improved compliance to the use of the recommended medications and changes in their dietary habits and lifestyles, which in turn improves their general health and well-being [Figure 3].



Fig 3: Pie chart showing advantages of early detection

Figure 3 presents the benefits of early detection and intervention in CKD patients with cardiovascular risks. It highlights aspects such as reduced morbidity, prevention of 'End-Stage Renal Disease (ESRD)', and improvement in the quality of life. By visually summarizing these benefits, the pie chart supports the argument for proactive screening and management of cardiovascular risk factors in CKD patients to improve overall outcomes

4. Interventional Approaches

The management strategies implemented on patients with CKD are intended to further reduce cardiovascular risks in patients. Others are the management of 'high blood pressure', the normalization of cholesterol and lipoprotein levels, and the control of metabolic complications. Adherence to diet change and exercise apart from medicinal use can, to a larger extent, decrease the impact of CVD. Early intervention improves not only the patient's life but also the trajectory of CKD and healthcare expenditure.

4.1 Pharmacological Interventions

Prescription Angiotensin- ACE inhibitors and ARBs are advised for patients with chronic kidney disease (CKD) because they make proteinuria decrease and halt the progression of kidney failure [41]. Furthermore, these drugs offer more or less tangible benefits to cardiovascular health, in particular, the prevention of heart failure as well as the perspective of myocardial infarction. Furthermore, ACE inhibitors and ARBs are coadministered with statins, a medication used in the management of

hyperlipidemia, a new finding in CKD patients, to reduce atherosclerotic cardiovascular disease risk [42].
Several recent investigations point to the fact that these pharmacological agents not only regulate conventional CV risk factors but also seem to afford renal protective properties due to anti-inflammatory and antioxidant properties [43].

Specific Therapeutic Approach for CKD Patients with Hypertension*:* "High blood pressure" is usual in patients with CKD and is considered one of the main predictors of cardiovascular events [44]. The decision on which antihypertensive to use should also be based on the renal function, electrolytes, and other co-morbidities of the patient. ACE inhibitors and, to a lesser extent, ARBs are the first-line therapy because of their positive effects on both the kidney and heart [40]. However, sometimes it is possible to attain normal blood pressure only by adding diuretics, beta-blockers, or calcium channel blockers to the medications [45]. Newer data also point to the fact that MRAs may offer further CV benefits, but their use should be accompanied by close monitoring of "serum potassium levels" [46].

4.2 Antiplatelet Therapy and Anticoagulation Considerations: Patients having CKD are at higher risk for developing thromboembolic events, and due care should be taken while prescribing antiplatelet and anticoagulant drugs. LDA is prescribed for CVD prevention and management, however, CKD patients are at a higher risk of bleeding and thus require caution and a tailored approach. Furthermore, several methods have been found to potentially reduce the development of stroke in patients with AF, which include NOACs [47]. Nevertheless, dose adjustments and close monitoring are needed to prevent adverse effects [47].

4.3 Non-Pharmacological Interventions

Dietary Modifications: In the primary as well as secondary treatment for CKD, nutrition intervention is a critical part. Reducing sodium and phosphate consumption is particularly critical for the prevention and treatment of CKD and its cardiovascular consequences [45]. Reducing the intake of sodium reduces hypertension which is an added risk factor to cardiovascular diseases. Also, moderation of phosphate intake may help to reduce the progress of embarrassing vascular calcification that affects most patients with CKD. Modern diet advice permits a daily intake of not more than 2 grams of sodium [45]. The dietary allowance for phosphate is moderate consumption or use of phosphate binder anticipating the deterioration of CKD and its concomitant cardiovascular ailments.
Lifestyle Changes: To reduce cardiovascular disease, the dietary supplementation of lifestyle modification strategies is important for patients with chronic kidney disease [46]. Tobacco smoking is contraindicated, this is because tobacco use worsens both CKD and cardiovascular complications related to the disease. Performing light to moderate exercises for at least 30 minutes daily can help improve the heart's status, decrease hypertension, especially in patients, and fight obesity. Besides, moderate and consistent exercise influences positive mental health, which is often seen in CKD patients as the condition is lifelong [47]. The aforementioned lifestyle changes allow for enhancing the state of CKD and CVD in a respective subject; thus, they should be encouraged.
Dialysis: For CKD stages 4 and 5, RRT is required in patients Choh JH MD. Currently, the main conventional methods of renal replacement therapy include hemodialysis and peritoneal dialysis with definite advantages and limitations of each [48]. While ESRD has various therapies of choice, kidney transplantation from a live donor is preferred because of its favorable efficacy, evidenced, an enhanced five-year cumulative patient survival rate as well as improved QoL in comparison to CAPD and HD. Its application is based on certain factors, which include the patient's preferences, their general health status, and the availability of the donors for transplant [48].

4.4 New Approaches and New Treatments

Therapies and treatment approaches for CVD in patients with CKD have, however, developed new therapies to show enhanced ways of handling the condition. One of the promising approaches in this regard is the application of drugs initially tested to control blood sugar – ‘Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. The SGLT2 inhibitors also have been found to have some cardiorenal benefits other than glycemic control that include; reduction of cardiovascular hospitalization due to hazards of heart failure and a decrease in the progression of CKD. This makes them a valuable tool in the management of cardiovascular risks of acumeters in CKD patients regardless of diabetes.

Secondly, GLP-1 receptor agonists, a further category of anti-diabetic drugs, have also reported considerable positive effects on CVD risks in patients with CKD. These agents also enhance glycemic control while offering anti-inflammatory and antioxidant properties needed in reversing atherosclerosis and cardiovascular complications of CKD.

Opportunities arise with the developments in other fields involving personalized medicine as well. Genetic indexing and biomolecular testing are on the rise and work in present-day therapies to make them personalized as regards gene and body makeup. This can be used to improve the therapy of patients with CKD to prevent those pathways that contribute to both kidney and cardiovascular diseases.

Last, but not least, artificial neural networks and machine learning algorithms are transforming the prognostication and control of CVD in CKD subjects. Thus, through the integration of EHRs, imaging data, and genomic data, AI models can risk stratifying patients at an earlier stage for accurate intervention and optimization of long-term benefits [49] [Table 6].

Table 6: Interventional Approaches

Intervention Type	Specific Agent/Approach	Indications/Conditions	Benefits	Risks/Considerations	References
Pharmacological Interventions	ACE Inhibitors and ARBs	CKD, Hypertension, Hyperlipidemia	Decrease proteinuria, delay renal function decline, cardiovascular benefits.	Risk of hyperkalemia, renal function monitoring required	[40, 41, 42, 43]
	Statins	Hyperlipidemia in CKD	Decrease the incidence of atherosclerotic CVD	Risk of statin-related side effects	[42]
	MRAs (Mineralocorticoid Receptor Antagonists)	Hypertension, CKD	Potential additional CV benefits	Requires monitoring of serum potassium levels	[46]
Antiplatelet Therapy and Anticoagulation	Low-Dose Aspirin	Primary and secondary prevention of CVD	Reduces thromboembolic events	Higher bleeding risk in CKD patients	[43]
	NOACs (Novel Oral Anticoagulants)	Atrial Fibrillation, CKD	Decrease the risk of stroke	Dose adjustments and monitoring needed	[47]
Non-Pharmacological Interventions	Dietary Modifications	CKD, CVD	Manage hypertension, control vascular calcification	Requires adherence to strict dietary limits	[45]
	Lifestyle Changes	CKD, CVD	Improve cardiovascular fitness, manage weight, enhance mental health	Requires commitment to smoking cessation and regular exercise	[46, 47]
	Dialysis	Stage 4 and 5 CKD	Renal replacement therapy, better "quality of life" with transplantation	Hemodialysis and peritoneal dialysis have specific risks	[48]
New Approaches and Treatments	SGLT2 Inhibitors	CKD, Heart Failure	Decrease heart failure hospitalization, delay CKD progression	Possible side effects, especially in nondiabetic patients	[49]
	GLP-1 Receptor Agonists	CKD, Cardiovascular Effects	Improve glycemic control, and provide athero-protective and anti-inflammatory effects.	Potential side effects, especially gastrointestinal	[49]
	Personalized Medicine/Genetic Research	CVD in CKD	Tailored treatment based on genetic profile and biomarkers	Requires advanced testing and analysis	[49]

5. Future Directions and Research Needs

To enhance the knowledge of and practice in managing CVD in CKD, the following research priorities should be considered for future study. There is an acute clinical need for a series of high-quality large sample-size RCTs that address the issue of early intervention in patients with CKD with CVD comorbidity [50]. Recent work does not always boast the methodological sophistication or sample size needed to develop rigorous, definitive practice parameters for addressing these disorders concurrently. Studies of this type should assess treatments medical and non-medical, and their chronic effects on cardiovascular and renal endpoints [51]

Other opportunities also involve the use of technology as a way of improving the management of CVD associated with CKD. There are many examples of how big data and advanced analytics technologies such as 'artificial intelligence (AI) and machine learning' could be utilized to enhance risk assessment [52] and therefore provide more target therapy based on patient characteristics including genomics and EHR. Another powerful area of research to explore in the future is the establishment of more recent and precise biomarkers for cardiovascular risk in CKD patients [53].

In light of the new clinical evidence, there is a definite necessity in issuing new policy recommendations and underlining the need for mass prescreening and timely primary interventions. General knowledge about cardio-renal connection and early adoption of prevention services will play a significant role in the reduction of, and improvement of CKD [54].

6. Conclusion

The association between CVD and CKD is a vast area of research that has major clinical relevance. Despite the amount of work that has been done in the study of this relationship, there is still a lot that is unknown. However, there are no large-scale, methodologically sound RCTs that would directly compare the effectiveness of early intervention strategies. Contemporary research often lacks the level of detail that would provide clear clinical guidelines, which underscores the importance of high-quality research that would establish best-practice standards. Moreover, the enhancement made in the effectiveness of early intervention measures has not been proven to be effective in the long run. Again, To overcome the lack of evidence about the benefits of early detection and management, and their influence on cardiovascular and kidney-related health outcomes, large-scale prospective trials should be designed. Closing this gap will be important to enhancing patients' health and quality of care. Applying artificial intelligence, the progress in technology can greatly contribute to CVD management in CKD patients based on data from electronic health, imaging, and genomics. Such improvements can result in enhanced diagnostic accuracy and timeliness, and therefore, improved treatments. Further, in the biomarkers discovery novel technologies will help in early identification and continuous tracking of cardiovascular threats that may enhance patient prognosis. From a policy perspective, there is a need to incorporate into clinical practice, recent research results. Going through these guidelines with the new diagnostic and treatment methods will help in offering the best to the patients. However, there is a lack of improvement in early detection at the population level. To prevent CVD in the CKD patient population, primary and secondary prevention programs should be reinforced, and public awareness of CVD risk factors in CKD patients should be raised. The following areas should therefore be focused on in future studies to enhance the management of CVD in CKD. By applying systematic search strategies in combination with the development of technologies and changes in policies, the prospects of better patient outcomes and Quality of Life Index are good.

7. References

1. Levey AS, Coresh J. Chronic Kidney Disease. *Lancet*. 2012;379(9811):165180. 10.1016/S01406736(11)601785.
2. Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl*. 2013;3(1):1150. 10.1038/kisup.2012.73.
3. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl*. 2013;3(1):1150. 10.1038/kisup.2012.73.
4. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol*. 2017;70(1):125. 10.1016/j.jacc.2017.04.052.
5. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. *Circulation*. 2020;141(9). 10.1161/CIR.0000000000000757.
6. Update, A. S. (2017). Heart disease and stroke statistics–2017 update. *Circulation*, *135*, e146-e603.
7. Lozano R, Naghavi M, Foreman K, et al. Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):20952128. 10.1016/S01406736(12)617280.
8. Chronic Kidney Disease Prognosis Consortium. (2010). Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *The Lancet*, *375*(9731), 2073-2081.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. *N Engl J Med*. 2004;351(13):12961305. 10.1056/NEJMoa041031.
10. London GM, Marty C, Marchais SJ, et al. Arterial Calcifications and Bone Histomorphometry in EndStage Renal Disease. *J Am Soc Nephrol*. 2004;15(7):19431951. 10.1097/01.ASN.0000132447.51015.74.
11. Agarwal, R. (2018). Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. *Nephrology Dialysis Transplantation*, *33*(10), 1690-1698.
12. Tonelli M, Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. *Ann Intern Med*. 2014;160(3):182189. 10.7326/M132453.
13. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. *Am J Med*. 2003;115(4):291-297. 10.1016/s0002-9343(03)00358-5.
14. Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, Bakris GL. Hypertension awareness, treatment, and control in chronic kidney disease. *Am J Med*. 2008;121(4):332-340. 10.1016/j.amjmed.2007.11.025.
15. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA*. 2011;305(24):2532-2539. 10.1001/jama.2011.861.
16. Bulbul, M. C., Dagel, T., Afsar, B., Ulusu, N. N., Kuwabara, M., Covic, A., & Kanbay, M. (2018). Disorders of lipid metabolism in chronic kidney disease. *Blood purification*, *46*(2), 144-152.
17. Li, Y., Wu, W., Liu, W., & Zhou, M. (2020). Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target. *Biomedicine & Pharmacotherapy*, *131*, 110712.
18. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M. IL-10, IL-6, and TNF-α: central factors in the altered cytokine network

of uremia—the good, the bad, and the ugly. *Kidney Int*. 2005;67(4):1216-1233. 10.1111/j.1523-1755.2005.00200.x.

19. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int*. 2007;71(5):438-441. 10.1038/sj.ki.5002079.
20. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296-1305. 10.1056/NEJMoa041031.
21. Sandhu, A., Soman, S., Hudson, M., & Besarab, A. (2010). Managing anemia in patients with chronic heart failure: what do we know? *Vascular health and risk management*, 237-252.
22. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Stimpel M. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. *Circulation*. 1997;96(12):3827-3832. 10.1161/01.cir.96.12.3827.
23. McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC, Norris KC, McFarlane SI, Johnson B, Shlipak MG. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. *Am Heart J*. 2008;156(2):277-283. 10.1016/j.ahj.2008.03.026.
24. Wang, A. Y. M., Lam, C. W. K., Chan, I. H. S., Wang, M., Lui, S. F., & Sanderson, J. E. (2010). Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. *Hypertension*, *56*(2), 210-216.
25. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The Framingham predictive instrument in chronic kidney disease. *J Am Coll Cardiol*. 2007;50(3):217-224. 10.1016/j.jacc.2007.03.037.
26. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation*. 2002;106(23):2941-2945. 10.1161/01.cir.0000038900.55128.c6.
27. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol*. 2002;39(4):695-701. 10.1016/s0735-1097(01)01872-8.
28. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation*. 2003;107(1):87-92. 10.1161/01.cir.0000042700.48749.37.
29. Herzog CA. Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. *Kidney Int Suppl*. 2003;84. 10.1046/j.1523-1755.63.s84.43.x.
30. Wanner, C., & Tonelli, M. (2014). Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. *Kidney Int*, *85*(6), 1303-1309.
31. DeFilippi CR, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Seliger SL, Heidenreich P, Wolfert RL. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA*. 2003;290(3):353-359. 10.1001/jama.290.3.353.
32. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation*. 2002;106(23):2941-2945. 10.1161/01.cir.0000038900.55128.c6.
33. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Cutrupi S, Bonanno G, Seminara G, Parlongo S, Rapisarda F, Fatuzzo P, Cataliotti S, Malatino LS. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. *J Am Soc Nephrol*. 2001;12(12):2768-2774. 10.1681/asn.v12122768.

34. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease?. *J Am Coll Cardiol*. 2002;39(4):695-701. 10.1016/s0735-1097(01)01872-8.
35. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, Hemmelgarn BR. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. *Lancet*. 2012;380(9844):807-814. 10.1016/S0140-6736(12)60572-8.
36. Brenner, B. M., Cooper, M. E., De Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., ... & Shahinfar, S. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *New England journal of medicine*, *345*(12), 861-869.
37. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Cardiovascular disease risk status in elderly persons with renal insufficiency. *Kidney Int*. 2002;62(3):997-1004. 10.1046/j.1523-1755.2002.00508.x.
38. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore J, Gassman J, Glassock R, Hebert L, Jamerson K, Kopple J, Kusek JW, Langford HG, Lewis J, Phillips RA, Toto R, Rostand SG, Wang SR, Walker WG, Rahman M. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA*. 2002;288(19):2421-2431. 10.1001/jama.288.19.2421.
39. Johansen KL, Chertow GM, Kutner NG, Dalrymple LS, Grimes BA, Kaysen GA. Low level of self-reported physical activity in ambulatory patients new to dialysis. *Kidney Int*. 2010;78(11):1164-1170. 10.1038/ki.2010.312/
40. 40. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. [10.1093/eurheartj/ehy339
41. 41. Kalaitzidis, R. G., & Elisaf, M. S. (2018). Treatment of hypertension in chronic kidney disease. Current hypertension reports, 20, 1-10. 10.1007/s11906-018-0857-6
42. 42. Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., ... & Deckers, J. W. (2009). The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Bmj, 338. 10.1136/bmj.b2376
43. Pallikadavath, S., Ashton, L., Brunskill, N. J., Burton, J. O., Gray, L. J., & Major, R. W. (2021). Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. European journal of preventive cardiology, 28(17), 1953-1960.10.1177/20474873211027264
44. Andò, G., & Capranzano, P. (2017). Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis. International journal of cardiology, 231, 162-169. 10.1016/j.ijcard.2017.01.032
45. Floege, J. (2016). Phosphate binders in chronic kidney disease: a systematic review of recent data. Journal of nephrology, 29(3), 329-340. 10.1007/s40620-016-0288-4
46. Wang, Y. J., Yeh, T. L., Shih, M. C., Tu, Y. K., & Chien, K. L. (2020). Dietary sodium intake and risk of cardiovascular disease: a systematic review and dose-response meta-analysis. Nutrients, 12(10), 2934. 10.3390/nu12102934
47. Ladhani, M., Craig, J. C., Irving, M., Clayton, P. A., & Wong, G. (2017). Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 32(3), 439-449. 10.1093/ndt/gfw401
48. Pannu, N., Klarenbach, S., Wiebe, N., Manns, B., Tonelli, M., & Alberta Kidney Disease Network. (2008). Renal replacement therapy in patients with acute renal failure: a systematic review. Jama, 299(7), 793-805.10.1001/jama.299.7.793
49. Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., ... & Zinman, B. (2018). Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus,

established cardiovascular disease, and chronic kidney disease. Circulation, 137(2), 119-129. 10.1161/CIRCULATIONAHA.117.032023

50. Saratzis, A., Harrison, S., Barratt, J., Sayers, R. D., Sarafidis, P. A., & Bown, M. J. (2015). Intervention associated acute kidney injury and long-term cardiovascular outcomes. American journal of nephrology, 42(4), 285-294.10.1159/000439941
51. Schena, F. P., Anelli, V. W., Abbrescia, D. I., & Di Noia, T. (2022). Prediction of chronic kidney disease and its progression by artificial intelligence algorithms. Journal of Nephrology, 35(8), 1953-1971.10.1007/s40620-022-01412-8
52. Siasos, G., Tousoulis, D., Michalea, S., Oikonomou, E., Kolia, C., Kioufis, S., ... & Stefanadis, C. (2012). Biomarkers determining cardiovascular risk in patients with kidney disease. Current medicinal chemistry, 19(16), 2555-2571.10.2174/092986712801766227
53. Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., ... & Tonelli, M. (2008). Guidelines for the management of chronic kidney disease. Cmaj, 179(11), 1154-1162. 10.1503/cmaj.080402
54. Stenvinkel, P. (2010). Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of internal medicine, 268(5), 456-464. 10.1111/j.1365-2796.2010.02255.x